WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals and part of Johnson Matthey Plc, for £256 million (or approximately $405 million) in cash. Based in Heysham, U.K., Alfa Aesar has 480 employees and operates in key research hubs in the United States, Germany, China, South Korea and India. The business generated sales of approximately £78 million (or $125 million) in 2014.
“The acquisition of Alfa Aesar enhances our existing portfolio of chemicals, solvents and reagents to support virtually every laboratory application – from research, to drug discovery and development, to production,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “In addition, customers will benefit from greater access to these products through our extensive global commercial reach.”
The transaction, which is expected to be completed by the end of 2015, is subject to customary closing conditions, including regulatory approvals. Alfa Aesar will be integrated into Thermo Fisher’s Laboratory Products and Services Segment.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
